Back

Acute and Post-Acute COVID-19 Outcomes Among Immunologically Naïve Adults During Delta Versus Omicron Waves

Doll, M. K.; Waghmare, A.; Heit, A.; Levenson Shakoor, B.; Kimball, L. E.; Ozbek, N.; Blazevic, R. L.; Mose, L.; Boonyaratanakornkit, J.; Stevens-Ayers, T. L.; Cornell, K.; Sheppard, B. D.; Hampson, E.; Sharmin, F.; Goodwin, B.; Dan, J. M.; Archie, T.; O'Connor, T.; Heckerman, D.; Schmitz, F.; Boeckh, M.; Crotty, S.

2022-11-14 infectious diseases
10.1101/2022.11.13.22282222 medRxiv
Show abstract

II.ImportanceThe U.S. arrival of the Omicron variant led to a rapid increase in SARS-CoV-2 infections. While numerous studies report characteristics of Omicron infections among vaccinated individuals and/or persons with a prior history of infection, comprehensive data describing infections among immunologically naive adults is lacking. ObjectiveTo examine COVID-19 acute and post-acute clinical outcomes among a well-characterized cohort of unvaccinated and previously uninfected adults who contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare outcomes with infections that occurred during the Delta wave. DesignA prospective cohort undergoing high-resolution symptom and virologic monitoring between June 2021 and September 2022 SettingMultisite recruitment of community-dwelling adults in 8 U.S. states ParticipantsHealthy, unvaccinated adults between 30 to 64 years of age without an immunological history of SARS-CoV-2 who were at high-risk of infection were recruited. Participants were followed for up to 48 weeks, submitting regular COVID-19 symptom surveys and nasal swabs for SARS-CoV-2 PCR testing. Exposure(s)Omicron (BA.1/BA.2 lineages) versus Delta SARS-CoV-2 infection, defined as a positive PCR that occurred during a period when the variant represented [&ge;]50% of circulating SARS-CoV-2 variants in the participants geographic region. Main Outcome(s) and Measure(s)The main outcomes examined were the prevalence and severity of acute ([&le;]28 days post-onset) and post-acute ([&ge;]5 weeks post-onset) symptoms. ResultsAmong 274 immunologically naive participants, 166 (61%) contracted SARS-CoV-2. Of these, 137 (83%) and 29 (17%) infections occurred during the Omicron- and Delta-predominant periods, respectively. Asymptomatic infections occurred among 6.7% (95% CI: 3.1%, 12.3%) of Omicron cases and 0.0% (95% CI: 0.0%, 11.9%) of Delta cases. Healthcare utilization among Omicron cases was 79% (95% CI: 43%, 92%, P =0.001) lower relative to Delta cases. Relative to Delta, Omicron infections also experienced a 56% (95% CI: 26%, 74%, P =0.004) and 79% (95% CI: 54%, 91%, P <0.001) reduction in the risk and rate of post-acute symptoms, respectively. Conclusions and RelevanceThese findings suggest that among previously immunologically naive adults, few Omicron (BA.1/BA.2) and Delta infections are asymptomatic, and relative to Delta, Omicron infections were less likely to seek healthcare and experience post-acute symptoms. KEY POINTSO_ST_ABSQuestionC_ST_ABSWhat are acute and post-acute outcomes among previously uninfected and unvaccinated adults who contracted Omicron (BA.1/BA.2), and how do these compare with Delta infections? FindingsIn this prospective cohort of 274 immunologically naive adults, 166 (61%) contracted SARS-CoV-2, with 9 (5.5%) asymptomatic infections. Compared with Delta, Omicron infections experienced a 79% relative reduction in healthcare utilization, and 56% and 79% relative reductions in the risk and rate of post-acute symptoms ([&ge;]5-weeks), respectively. MeaningThese findings suggest among immunologically naive adults, few infections are asymptomatic, and relative to Delta, Omicron infections have lower likelihoods of severe illness and post-acute symptoms.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Clinical Infectious Diseases
231 papers in training set
Top 0.1%
32.5%
2
Open Forum Infectious Diseases
134 papers in training set
Top 0.1%
8.3%
3
JAMA Network Open
127 papers in training set
Top 0.3%
6.7%
4
Annals of Internal Medicine
27 papers in training set
Top 0.1%
6.2%
50% of probability mass above
5
The Lancet
16 papers in training set
Top 0.1%
4.2%
6
The Journal of Infectious Diseases
182 papers in training set
Top 0.8%
4.1%
7
The Lancet Infectious Diseases
71 papers in training set
Top 0.6%
3.9%
8
BMC Infectious Diseases
118 papers in training set
Top 1%
3.5%
9
BMJ
49 papers in training set
Top 0.4%
2.3%
10
PLOS ONE
4510 papers in training set
Top 49%
2.0%
11
American Journal of Epidemiology
57 papers in training set
Top 0.6%
1.9%
12
PLOS Medicine
98 papers in training set
Top 2%
1.9%
13
Influenza and Other Respiratory Viruses
44 papers in training set
Top 0.2%
1.6%
14
BMJ Open
554 papers in training set
Top 10%
1.3%
15
Emerging Infectious Diseases
103 papers in training set
Top 2%
1.2%
16
The Lancet Microbe
43 papers in training set
Top 0.9%
1.2%
17
International Journal of Infectious Diseases
126 papers in training set
Top 3%
0.9%
18
BMC Public Health
147 papers in training set
Top 5%
0.9%
19
Clinical Microbiology and Infection
60 papers in training set
Top 1%
0.8%
20
Nature Communications
4913 papers in training set
Top 62%
0.8%
21
Journal of Infection
71 papers in training set
Top 3%
0.7%
22
EClinicalMedicine
21 papers in training set
Top 1%
0.7%
23
BMC Medicine
163 papers in training set
Top 7%
0.7%
24
Journal of Medical Virology
137 papers in training set
Top 5%
0.6%
25
New England Journal of Medicine
50 papers in training set
Top 1.0%
0.6%